HC Wainwright & Co. Initiates Coverage On Trevi Therapeutics with Buy Rating, Announces Price Target of $6

Benzinga · 08/30 15:52
HC Wainwright & Co. analyst Oren Livnat initiates coverage on Trevi Therapeutics (NASDAQ:TRVI) with a Buy rating and announces Price Target of $6.